

# Albert Pares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4987711/publications.pdf>

Version: 2024-02-01

355  
papers

19,167  
citations

13099

68  
h-index

12946

131  
g-index

375  
all docs

375  
docs citations

375  
times ranked

11518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	7.3	1,553
2	EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. <i>Journal of Hepatology</i> , 2009, 51, 237-267.	3.7	1,540
3	Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2006, 130, 715-720.	1.3	649
4	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, 172-193.	3.7	608
5	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	1.3	470
6	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	7.3	452
7	S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. <i>Journal of Hepatology</i> , 1999, 30, 1081-1089.	3.7	428
8	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	1.3	365
9	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
10	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	21.4	339
11	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	1.3	330
12	Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. <i>Hepatology</i> , 2000, 32, 36-42.	7.3	329
13	Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. <i>Journal of Hepatology</i> , 1998, 28, 615-621.	3.7	289
14	Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 1205-1211.	1.5	280
15	Histological course of alcoholic hepatitis. <i>Journal of Hepatology</i> , 1986, 2, 33-42.	3.7	271
16	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
17	Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. <i>Journal of Hepatology</i> , 2000, 32, 561-566.	3.7	254
18	Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury. <i>Hepatology</i> , 1990, 12, 1295-1299.	7.3	242

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	21.4	230
20	Effects of long-term rifampicin administration in primary biliary cirrhosis. <i>Gastroenterology</i> , 1992, 102, 2077-2080.	1.3	227
21	COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS. <i>Lancet, The</i> , 1989, 333, 574-576.	13.7	207
22	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	7.3	204
23	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 12-16.	3.7	199
24	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 573-577.	3.7	163
25	S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. <i>Hepatology</i> , 1992, 16, 1022-1027.	7.3	156
26	Epidemiology of primary sclerosing cholangitis in Spain. <i>Journal of Hepatology</i> , 1994, 21, 787-791.	3.7	153
27	A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. <i>Journal of Hepatology</i> , 2004, 40, 40-46.	3.7	152
28	HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. <i>Tissue Antigens</i> , 1999, 53, 459-469.	1.0	151
29	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	3.7	148
30	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	12.1	139
31	Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 european primary sclerosing cholangitis patients. <i>Journal of Hepatology</i> , 2000, 32, 32.	3.7	136
32	Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method. <i>Hepatology</i> , 1985, 5, 815-818.	7.3	125
33	Changing nomenclature for PBC: From "cirrhosis"™ to "cholangitis"™. <i>Hepatology</i> , 2015, 62, 1620-1622.	7.3	125
34	Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. <i>Gut</i> , 2005, 54, 528-532.	12.1	123
35	Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2010, 138, 2348-2356.	1.3	115
36	Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 200-205.	3.7	111

#	ARTICLE	IF	CITATIONS
37	Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1105-1110.	0.4	111
38	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , 2015, 62, 188-197.	7.3	106
39	Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: A randomized controlled trial. <i>Hepatology</i> , 1991, 14, 1090-1096.	7.3	105
40	Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. <i>Journal of Hepatology</i> , 2010, 53, 307-312.	3.7	104
41	Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. <i>Hepatology</i> , 1988, 8, 930-938.	7.3	101
42	Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. <i>Gut</i> , 2001, 49, 288-294.	12.1	97
43	Portal hypertension in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1987, 5, 292-298.	3.7	96
44	Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence To That in Hepatitis C Virus-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1160-1163.	0.4	96
45	Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2268-2274.	0.4	96
46	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015, 149, 1627-1629.	1.3	96
47	Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. <i>Gastroenterology</i> , 1986, 90, 1241-1246.	1.3	94
48	Hepatitis C Virus Infection in Patients with Nonalcoholic Chronic Liver Disease. <i>Annals of Internal Medicine</i> , 1990, 112, 921.	3.9	94
49	Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. <i>Liver International</i> , 2014, 34, 197-203.	3.9	94
50	Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. <i>American Journal of Gastroenterology</i> , 2018, 113, 49-55.	0.4	94
51	Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years. <i>Gastroenterology</i> , 1997, 113, 219-224.	1.3	93
52	Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. <i>Hepatology</i> , 2009, 50, 1162-1168.	7.3	93
53	Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 673-677.	3.7	90
54	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	3.7	85

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1950-1956.e1.	4.4	84
56	Collagen-Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 731-738.	2.8	82
57	Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: Effect on transcription factors AP-1 and NF- $\kappa$ B. <i>Hepatology</i> , 1999, 30, 1473-1480.	7.3	82
58	Soil Organic Carbon is Increased in Mixed-Species Plantations of Eucalyptus and Nitrogen-Fixing Acacia. <i>Ecosystems</i> , 2013, 16, 123-132.	3.4	82
59	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	1.3	82
60	Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2021, 160, 734-743.e6.	1.3	82
61	Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2013, 58, 2070-2078.	7.3	81
62	Natural history of primary biliary cirrhosis. <i>Clinics in Liver Disease</i> , 2003, 7, 779-794.	2.1	80
63	Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. <i>Journal of Hepatology</i> , 2000, 32, 374-380.	3.7	79
64	Osteoporosis in chronic liver disease. <i>Liver International</i> , 2018, 38, 776-785.	3.9	79
65	Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. <i>Hepatology</i> , 2002, 35, 652-657.	7.3	77
66	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	3.7	77
67	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.4	74
68	Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines. <i>Nature Communications</i> , 2019, 10, 2150.	12.8	73
69	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. <i>Clinical Science</i> , 1992, 83, 695-700.	4.3	72
70	New ELISA for Detecting Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies. <i>Clinical Chemistry</i> , 2009, 55, 978-985.	3.2	71
71	Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. <i>Journal of Hepatology</i> , 1998, 28, 54-60.	3.7	68
72	Sodium fluoride prevents bone loss in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1992, 15, 345-349.	3.7	67

#	ARTICLE	IF	CITATIONS
73	Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 723-732.	3.7	66
74	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	3.7	66
75	Collagen type I $\alpha$ 1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. <i>Hepatology</i> , 2001, 33, 554-560.	7.3	64
76	Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium <i>gordonae</i> and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2004, 22, 353-362.	6.5	64
77	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.4	64
78	Renal tubular acidosis in primary biliary cirrhosis. <i>Gastroenterology</i> , 1981, 80, 681-686.	1.3	61
79	The HLA-DR3,DQ2 Heterozygous Genotype is Associated with an Accelerated Progression of Primary Sclerosing Cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 886-890.	1.5	61
80	Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment. <i>Clinics in Liver Disease</i> , 2008, 12, 407-424.	2.1	61
81	Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. <i>Hepatology</i> , 2011, 54, 2104-2113.	7.3	61
82	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1170-1178.e6.	4.4	61
83	Financial Goals and Debt Ratio Determinants: A Survey of Practice in Five Countries. <i>Financial Management</i> , 1975, 4, 27.	2.7	60
84	Vertebral fractures and osteopenia in chronic alcoholic patients. <i>Calcified Tissue International</i> , 1995, 57, 111-114.	3.1	60
85	Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. <i>European Journal of Clinical Investigation</i> , 1997, 27, 667-672.	3.4	59
86	Liver and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 84-94.	3.0	58
87	Influence of liver disease on hepatic alcohol and aldehyde dehydrogenases. <i>Gastroenterology</i> , 1989, 97, 708-714.	1.3	57
88	Lithocholic acid downregulates vitamin D effects in human osteoblasts. <i>European Journal of Clinical Investigation</i> , 2010, 40, 25-34.	3.4	57
89	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. <i>Hepatology</i> , 2016, 63, 644-659.	7.3	57
90	2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID. <i>Journal of Hepatology</i> , 2010, 52, S1-S2.	3.7	56

#	ARTICLE	IF	CITATIONS
91	Disulfiram-induced hepatitis. Report of four cases and review of the literature. <i>Journal of Hepatology</i> , 1994, 21, 853-857.	3.7	55
92	Enhanced DNA Binding and Activation of Transcription Factors NF- $\kappa$ B and AP-1 by Acetaldehyde in HEPG2 Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 14684-14690.	3.4	55
93	Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. <i>Clinical Biochemistry</i> , 2007, 40, 645-650.	1.9	55
94	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
95	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 321-329.	3.7	55
96	FRAXA premutation associated with premature ovarian failure. , 1996, 64, 373-375.		54
97	Prevalence and Mechanisms of Hyperhomocysteinemia in Chronic Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1044-1048.	2.4	54
98	Bone mass improves in alcoholics after 2 years of abstinence. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 1607-1612.	2.8	54
99	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , 2017, 37, 1554-1561.	3.9	54
100	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
101	28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC. <i>Journal of Hepatology</i> , 2011, 54, S13.	3.7	52
102	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , 2007, 45, 1583-1583.	7.3	51
103	Validity of self-reported alcohol consumption in the emergency room: data from the United States, Mexico and Spain.. <i>Journal of Studies on Alcohol and Drugs</i> , 1992, 53, 203-207.	2.3	50
104	Pulmonary involvement in primary biliary cirrhosis.. <i>Thorax</i> , 1981, 36, 208-212.	5.6	48
105	Treatment of bone disorders in liver disease. <i>Journal of Hepatology</i> , 2006, 45, 445-453.	3.7	48
106	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
107	Management of osteoporosis in liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 438-445.	1.5	44
108	Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration. <i>Journal of Hepatology</i> , 1994, 21, 292-298.	3.7	43

#	ARTICLE	IF	CITATIONS
109	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
110	Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. <i>Critical Care</i> , 2009, 13, R8.	5.8	40
111	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 521-528.	1.5	40
112	Hepatitis G virus infection in chronic liver disease. <i>Gut</i> , 1998, 42, 107-111.	12.1	38
113	Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 311-315.	1.6	38
114	Sex Differences Associated with Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	37
115	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
116	Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 24-28.	3.7	36
117	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	1.5	36
118	Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000, 33, 528-536.	3.7	36
119	Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. <i>Hepatology</i> , 2015, 62, 1237-1248.	7.3	34
120	Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. <i>American Journal of Gastroenterology</i> , 2017, 112, 114-119.	0.4	34
121	Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1993, 17, 48-53.	2.4	33
122	Acetaldehyde activates the promoter of the mouse $\alpha_2(I)$ collagen gene*1. <i>Hepatology</i> , 1994, 19, 498-503.	7.3	33
123	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
124	Acetaldehyde activates the promoter of the mouse $\alpha_2(I)$ collagen gene. <i>Hepatology</i> , 1994, 19, 498-503.	7.3	32
125	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.4	30
126	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	4.4	30



#	ARTICLE	IF	CITATIONS
127	Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000, 33, 528-536.	3.7	29
128	TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency. <i>Laboratory Investigation</i> , 2015, 95, 223-236.	3.7	29
129	Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain. <i>American Journal of Gastroenterology</i> , 2004, 99, 763-764.	0.4	28
130	Patients with cirrhosis and ascites have false values of bone density. <i>Osteoporosis International</i> , 2012, 23, 1481-1487.	3.1	28
131	Changing nomenclature for PBC: from "cirrhosis"™ to "cholangitis"™. <i>Gut</i> , 2015, 64, 1671-1672.	12.1	28
132	Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 230.	1.6	28
133	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	12.1	28
134	Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. <i>Journal of Viral Hepatitis</i> , 2005, 12, 648-654.	2.0	27
135	Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. <i>Liver International</i> , 2013, 33, 1029-1038.	3.9	27
136	Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1725-1733.	2.8	27
137	Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. <i>Hepatology</i> , 1996, 24, 1399-1403.	7.3	27
138	Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1160-1163.	0.4	26
139	Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1206-1214.	3.4	26
140	Effects of prolonged ethanol intake and malnutrition on rat pancreas.. <i>Gut</i> , 1996, 38, 285-292.	12.1	25
141	Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2268-2274.	0.4	24
142	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2819-2821.	4.4	24
143	Carbohydrate-Deficient Transferrin as a Marker of Alcohol Consumption in Male Patients with Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 923-927.	2.4	23
144	Characterization of peptides and proteins in commercial HSA solutions. <i>Proteomics</i> , 2010, 10, 172-181.	2.2	22

#	ARTICLE	IF	CITATIONS
145	Old and Novel Therapies for Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 341-351.	3.6	22
146	Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 5381.	3.3	22
147	Drinking in the Injury Event: A Comparison of Emergency Room Populations in the United States, Mexico, and Spain. <i>Substance Use and Misuse</i> , 1993, 28, 931-945.	0.6	21
148	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2150-2157.	0.4	21
149	Alcoholic foamy degeneration in Spain. Prevalence and clinico-pathological features. <i>Liver</i> , 1989, 9, 79-85.	0.1	21
150	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. <i>Frontiers in Immunology</i> , 2019, 10, 662.	4.8	21
151	Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1634-1641.	0.4	21
152	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
153	Quantitative measurement of fibrosis in pancreatic tissue. <i>International Journal of Gastrointestinal Cancer</i> , 1991, 10, 23-29.	0.4	19
154	High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 347-354.	2.7	19
155	Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 254-262.	6.5	19
156	Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats. <i>Hepatology</i> , 1992, 16, 815-819.	7.3	17
157	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	4.4	17
158	Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. <i>Gene</i> , 2020, 725, 144167.	2.2	17
159	Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 1988, 6, 15-22.	3.7	16
160	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	4.4	16
161	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. <i>Endocrine</i> , 2010, 37, 322-328.	2.3	15
162	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.9	15

#	ARTICLE	IF	CITATIONS
163	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1121-1129.	3.9	15
164	Neighborhood differences in psychoses: Prevalence of psychotic disorders in two socially-differentiated metropolitan areas of Barcelona. <i>Schizophrenia Research</i> , 2009, 112, 143-148.	2.0	14
165	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. <i>Endocrine</i> , 2010, 37, 180-186.	2.3	14
166	Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus. <i>PLoS ONE</i> , 2011, 6, e21850.	2.5	14
167	Colangitis biliar primaria. <i>Medicina Clínica</i> , 2018, 151, 242-249.	0.6	14
168	Promoter hypermethylation of the AE2/SLC4A2 gene in PBC. <i>JHEP Reports</i> , 2019, 1, 145-153.	4.9	14
169	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.4	14
170	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 2250-2257.	0.4	14
171	Drinking patterns and problems: a comparison of emergency room populations in the United States and Spain. <i>Drug and Alcohol Dependence</i> , 1991, 29, 5-15.	3.2	13
172	Primary biliary cholangitis and bone disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 63-70.	2.4	13
173	Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestaticâ€induced osteoporosis. <i>Liver International</i> , 2020, 40, 2767-2775.	3.9	13
174	S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. <i>Clinical Science</i> , 2000, 99, 315-320.	4.3	12
175	Enteroendocrine cells are a potential source of serum autotaxin in men. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 696-704.	3.8	12
176	Acute Thallium Poisoning: An Evaluation of Different Forms of Treatment. <i>Journal of Toxicology: Clinical Toxicology</i> , 1982, 19, 1015-1021.	1.5	11
177	Lymphocytotoxic antibodies in primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1985, 30, 829-833.	2.3	11
178	Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis. <i>Hepatology</i> , 1988, 8, 837-844.	7.3	11
179	Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Journal of Hepatology</i> , 2018, 68, S38.	3.7	11
180	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. <i>World Journal of Gastroenterology</i> , 2012, 18, 4855.	3.3	11

#	ARTICLE	IF	CITATIONS
181	Prediction of alcohol-related casualties in the emergency room: a U.S.-Spain comparison.. Journal of Studies on Alcohol and Drugs, 1993, 54, 308-314.	2.3	10
182	Usability Evaluation of the Interactive Personal Patient Profile-Prostate Decision Support System With African American Men. Journal of the National Medical Association, 2010, 102, 290-302.	0.8	10
183	P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis. Journal of Hepatology, 2015, 62, S798-S799.	3.7	10
184	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of falseâ€positive antibodies. Liver International, 2020, 40, 558-564.	3.9	10
185	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100191.	4.9	10
186	Extracorporeal liver support in severe alcoholic hepatitis. World Journal of Gastroenterology, 2014, 20, 8011.	3.3	10
187	An unexpected transformation by reaction of congested Î±-(o-nitrophenyl) ketones with tris (dimethylamino) methane. A new heterocyclic system: 6,1. Tetrahedron, 1994, 50, 9769-9774.	1.9	9
188	Zinc Administration Improves Gastric Alcohol Dehydrogenase Activity and First-Pass Metabolism of Ethanol in Alcohol-Fed Rats. Alcoholism: Clinical and Experimental Research, 1997, 21, 1619-1622.	2.4	9
189	OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC. Gut, 2011, 60, A50-A50.	12.1	9
190	Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?. Clinical Liver Disease, 2014, 3, 29-33.	2.1	9
191	Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. Digestive Diseases, 2015, 33, 125-133.	1.9	9
192	Esophageal dysfunction in primary biliary cirrhosis. Journal of Hepatology, 1988, 7, 362-367.	3.7	8
193	Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis. Pancreas, 1994, 9, 270-274.	1.1	8
194	High Bilirubin Levels Interfere with Serum Tartrate-Resistant Acid Phosphatase Determination: Relevance as a Marker of Bone Resorption in Jaundiced Patients. Calcified Tissue International, 1999, 64, 301-303.	3.1	8
195	964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC). Journal of Hepatology, 2012, 56, S377.	3.7	8
196	The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time. Journal of Hepatology, 2017, 66, S543-S544.	3.7	8
197	Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases. Bone, 2022, 162, 116483.	2.9	8
198	Synthesis and Degradation of Collagen in Pancreatic Fibrogenesis. Pancreas, 1999, 18, 34-38.	1.1	7

#	ARTICLE	IF	CITATIONS
199	S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. <i>Clinical Science</i> , 2000, 99, 315.	4.3	7
200	Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid. <i>Journal of Hepatology</i> , 2001, 34, 189-190.	3.7	7
201	Duration and severity of the disease but not menopausal status are the main risk factors for osteoporosis in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 154-155.	3.7	7
202	Novel Treatment Strategies for Primary Biliary Cholangitis. <i>Seminars in Liver Disease</i> , 2017, 37, 060-072.	3.6	7
203	Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis “ even in patients without biochemical improvements. <i>Journal of Hepatology</i> , 2018, 68, S8.	3.7	7
204	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100081.	4.0	7
205	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	3.9	7
206	<i>Mycobacterium gordonae</i> DNA in liver tissue of patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, S87.	3.7	6
207	Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2001, 34, 187-188.	3.7	6
208	Expected developments in hepatology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 957-970.	2.4	6
209	184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE. <i>Journal of Hepatology</i> , 2010, 52, S79.	3.7	6
210	URINE ETHANOL ASSESSMENT: A HELPFUL METHOD FOR CONTROLLING ABSTINENCE IN ALCOHOLIC LIVER DISEASE. <i>Alcohol and Alcoholism</i> , 1988, 23, 403-407.	1.6	5
211	The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 66, S355-S356.	3.7	5
212	Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC). <i>Journal of Hepatology</i> , 2018, 68, S111-S112.	3.7	5
213	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis“Related Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1392-1402.	4.3	5
214	Synoptic Effects on the Local Winds in Todos Santos Bay: A Case Study. <i>Monthly Weather Review</i> , 1983, 111, 1494-1500.	1.4	4
215	<i>Mycobacteria</i> - related to the aetiopathogenesis of primary biliary cirrhosis?. <i>Journal of Hepatology</i> , 1996, 24, 125.	3.7	4
216	Low platelet count influences the performance of the different biochemical criteria of ursodeoxycholic acid therapy response in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 66, S355.	3.7	4

#	ARTICLE	IF	CITATIONS
217	Primary biliary cholangitis. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 242-249.	0.2	4
218	GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. <i>Journal of Hepatology</i> , 2019, 70, e84.	3.7	4
219	Effects of zinc on liver fibrosis and vitamin a metabolism in rats. <i>Journal of Hepatology</i> , 1988, 7, S4.	3.7	3
220	Pentoxifylline prevents liver fibrosis but induces cellular damage in carbon tetrachloride injured rats. <i>Journal of Hepatology</i> , 1994, 21, S136.	3.7	3
221	Hepatic Fibrogenic Activity in Chronic Alcoholic Pancreatitis. <i>Pancreas</i> , 1999, 19, 276-280.	1.1	3
222	Cross-reactivity between mycobacterium gordonae and PDC-E2, the major target of anti-mitochondrial antibody, is present in Spanish but not British patients with PBC. <i>Journal of Hepatology</i> , 2001, 34, 19.	3.7	3
223	Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 155.	3.7	3
224	535 HIGH BILIRUBIN REDUCES CELL SURVIVAL AND DIFFERENTIATION OF PRIMARY HUMAN OSTEOBLASTS. IS THIS EFFECT APPLICABLE TO THE SERUM OF CHRONIC CHOLESTATIC PATIENTS?. <i>Journal of Hepatology</i> , 2010, 52, S214-S215.	3.7	3
225	952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC). <i>Journal of Hepatology</i> , 2012, 56, S372.	3.7	3
226	O5 PRIMARY SCLEROSING CHOLANGITIS FROM A GLOBAL PERSPECTIVE – A MULTICENTER, RETROSPECTIVE, OBSERVATIONAL STUDY OF THE INTERNATIONAL PSC STUDY GROUP. <i>Journal of Hepatology</i> , 2014, 60, S3.	3.7	3
227	O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY. <i>Journal of Hepatology</i> , 2014, 60, S55.	3.7	3
228	P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S786.	3.7	3
229	P1201 : Long-term therapy with bezafibrate and ursodeoxycholic acid is insufficient for preventing disease progression in patients with advanced primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S806.	3.7	3
230	Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in 3529 Patients with Primary Biliary Cholangitis. <i>Journal of Hepatology</i> , 2016, 64, S633-S634.	3.7	3
231	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.3	3
232	Alendronate versus etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment. <i>Journal of Hepatology</i> , 2001, 34, 19.	3.7	3
233	Serum procollagen type III peptide does not reflect hepatic collagen content in alcoholics with inactive cirrhosis. <i>Journal of Hepatology</i> , 1985, 1, S252.	3.7	2
234	Nuclear lamina antibodies in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1986, 3, S28.	3.7	2

#	ARTICLE	IF	CITATIONS
235	Liver diseases associated with autoantibodies directed to nuclear envelope components. <i>Hepatology</i> , 1989, 9, 911-912.	7.3	2
236	Effects of zinc on hepatic lipid peroxidation and liver fibrosis in carbon tetrachloride-treated rats. <i>Journal of Hepatology</i> , 1990, 11, S14.	3.7	2
237	A simple method for assessing timing of liver transplantation in primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 1991, 13, S124.	3.7	2
238	Serum Amino-Terminal Propeptide of Type III Procollagen Levels in Chronic Pancreatitis. <i>Pancreas</i> , 1996, 12, 153-158.	1.1	2
239	The molecular adsorbent recirculating system (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 150.	3.7	2
240	849 PATIENTS WITH ASCITES HAVE FALSE VALUES OF BONE MINERAL DENSITY AT THE CENTRAL SKELETON. A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2010, 52, S331.	3.7	2
241	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-10.	0.6	2
242	P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY. <i>Journal of Hepatology</i> , 2014, 60, S192-S193.	3.7	2
243	Bezafibrate Alleviates Pruritus and Decreases Specific Circulating Metabolites in Patients with Primary Biliary Cholangitis. <i>Journal of Hepatology</i> , 2016, 64, S429.	3.7	2
244	Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. <i>Digestive and Liver Disease</i> , 2019, 51, e19.	0.9	2
245	Practical management of primary biliary cholangitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.3	2
246	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
247	Primary Sclerosing Cholangitis. <i>Southern Medical Journal</i> , 1978, 71, 855-856.	0.7	1
248	Nonoliguric acute renal failure in an intensive care unit. <i>Intensive Care Medicine</i> , 1980, 6, 244-245.	8.2	1
249	Predictive value of histological features in the progression of alcoholic fatty liver. <i>Journal of Hepatology</i> , 1987, 5, S177.	3.7	1
250	Effects of zinc administration on liver fibrogenesis and collagenolysis in rats induced to cirrhosis. <i>Journal of Hepatology</i> , 1989, 9, S36.	3.7	1
251	Effects of S-adenosylmethionine on liver fibrosis in rats. <i>Journal of Hepatology</i> , 1991, 13, S124.	3.7	1
252	Are hepatitis C virus antibodies involved in chronic liver diseases other than non-A, non-B hepatitis?. <i>Hepatology</i> , 1991, 14, 1303-1304.	7.3	1

#	ARTICLE	IF	CITATIONS
253	Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas. Alcohol, 1996, 13, 227-231.	1.7	1
254	Vitamin D receptor gene polymorphism and bone mass in primary biliary cirrhosis. Journal of Hepatology, 1998, 28, 140.	3.7	1
255	Age, obesity and hyperglycemia but not ethanol intake are the main risk factors for developing fatty liver in men. Journal of Hepatology, 2000, 32, 210.	3.7	1
256	Hyperhomocysteinemia in chronic alcoholism. Relationship to liver damage. Journal of Hepatology, 2002, 36, 143-144.	3.7	1
257	Improvement in systemic hemodynamics after albumin dialysis is associated with a decrease in vasoactive agents. Journal of Hepatology, 2003, 38, 67.	3.7	1
258	Albumin dialysis decreases aromatic amino acids and improves hepatic encephalopathy in patients with severe liver dysfunction. Journal of Hepatology, 2003, 38, 67.	3.7	1
259	123 PRESENTATION AND NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS IN SPAIN: EXPERIENCE OVER 35 YEARS. Journal of Hepatology, 2008, 48, S54.	3.7	1
260	874 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2008, 48, S328.	3.7	1
261	61 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS. COMPARATIVE ANALYSIS FROM TWO EUROPEAN REFERRAL CENTERS. Journal of Hepatology, 2009, 50, S26.	3.7	1
262	Reply:. Hepatology, 2010, 52, 2239-2239.	7.3	1
263	P373 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS. EFFECTS OF ALBUMIN DIALYSIS. Journal of Hepatology, 2014, 60, S192.	3.7	1
264	P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study. Journal of Hepatology, 2015, 62, S796-S797.	3.7	1
265	Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis. Journal of Hepatology, 2016, 64, S642-S643.	3.7	1
266	A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude?. Digestive and Liver Disease, 2018, 50, 26.	0.9	1
267	Pregnancy and autoimmune hepatitis: presentation and outcomes. Journal of Hepatology, 2018, 68, S233.	3.7	1
268	FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. Journal of Hepatology, 2019, 70, e404.	3.7	1
269	Clustering Reveals the Prognostic Role of Serum Albumin Values Within the Normal Range in Patients with Primary Biliary Cholangitis. Digestive and Liver Disease, 2021, 53, S5.	0.9	1
270	Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. , 2009, , 259-269.		1



#	ARTICLE	IF	CITATIONS
271	Renal Tubular Function in Chronic Cholestasis. , 1979, , 132-136.		0
272	Evaluation of a quantitative simple method for measuring fibrosis in human liver biopsies. Journal of Hepatology, 1985, 1, S70.	3.7	0
273	Effects of alcoholism and liver injury on hepatic alcohol and acetaldehyde metabolizing enzymes. Journal of Hepatology, 1985, 1, S301.	3.7	0
274	Influence of liver function and alcohol dehydrogenase activity on ethanol metabolism in chronic alcoholics. Journal of Hepatology, 1985, 1, S299.	3.7	0
275	Relationship between hepatic collagen and portal pressure in alcoholic liver disease. Journal of Hepatology, 1985, 1, S205.	3.7	0
276	Esophageal motility disturbances in primary biliary cirrhosis. Journal of Hepatology, 1986, 3, S27.	3.7	0
277	Factors influencing blood acetaldehyde levels after ethanol administration in chronic alcoholics. Journal of Hepatology, 1987, 5, S50.	3.7	0
278	Influence of dietary factors in the development of alcoholic hepatitis. Journal of Hepatology, 1987, 5, S170.	3.7	0
279	Influence of abstinence on serum procollagen type III peptide levels in alcoholic liver disease. Journal of Hepatology, 1989, 9, S133.	3.7	0
280	Low bone mineral density in primary biliary cirrhosis. Influence of intestinal calcium absorption and bone formation. Journal of Hepatology, 1989, 9, S159.	3.7	0
281	Fibrogenesis and collagenolysis in rats induced to liver cirrhosis. Journal of Hepatology, 1989, 9, S102.	3.7	0
282	Effects of long-term rifampicin administration in primary biliary cirrhosis. Journal of Hepatology, 1989, 9, S105.	3.7	0
283	Association between the histocompatibility antigens and the severity of alcoholic liver disease. Journal of Hepatology, 1989, 9, S133.	3.7	0
284	Influence of dietary zinc on hepatic collagen and prolyl-hydroxylase activity in alcoholic rats. Journal of Hepatology, 1990, 11, S26.	3.7	0
285	Rifampicin versus phenobarbital for treatment of pruritus in primary biliary cirrhosis. Results of a crossover randomized trial. Journal of Hepatology, 1990, 10, P3.	3.7	0
286	Protective effect of zinc on hepatic lipid peroxidation and fibrogenesis in CCL4-treated rats. A possible role for metallothioneins. Journal of Hepatology, 1991, 13, S16.	3.7	0
287	A prognostic index (PI) for patient selection and timing of liver transplantation in cirrhosis with ascites. Journal of Hepatology, 1991, 13, S32.	3.7	0
288	Prognostic value of the aminopyrine breath test and abstinence in severe alcoholic liver disease. Journal of Hepatology, 1994, 21, S81.	3.7	0

#	ARTICLE	IF	CITATIONS
289	Carbohydrate-deficient transferrin (CDT) as a marker of alcohol consumption in patients with liver disease. <i>Journal of Hepatology</i> , 1994, 21, S86.	3.7	0
290	Collagen-related markers of bone turnover reflect liver collagen metabolism in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, S167.	3.7	0
291	The role of metalloproteinases in CCl4 induced fibrosis. Influence of zinc administration. <i>Journal of Hepatology</i> , 1998, 28, 86.	3.7	0
292	Circulating metalloproteinases and their tissue inhibitors in alcoholic liver disease. Relationship to liver fibrosis. <i>Journal of Hepatology</i> , 1998, 28, 173.	3.7	0
293	Serum markers of fibrogenesis and collagenolysis in patients with chronic liver disease. <i>Journal of Hepatology</i> , 1998, 28, 174.	3.7	0
294	Time dependent neural network prognostic model for Primary Sclerosing Cholangitis (PSC). <i>Journal of Hepatology</i> , 2000, 32, 207.	3.7	0
295	New time dependent prognostic models for Primary Sclerosing Cholangitis (PSC). <i>Journal of Hepatology</i> , 2000, 32, 207.	3.7	0
296	Influence of the genetic polymorphism of collagen type I A2 in the development of alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2001, 34, 200.	3.7	0
297	Genetic polymorphisms of alcohol metabolizing enzymes do not influence the development of alcoholic liver disease. <i>Journal of Hepatology</i> , 2002, 36, 143.	3.7	0
298	Blood levels of antioxidant vitamins in alcoholic liver disease. Relationship to liver damage. <i>Journal of Hepatology</i> , 2003, 38, 191.	3.7	0
299	641 A study of primary biliary cirrhosis specific antinuclear antibodies in predicting disease severity and outcome. <i>Journal of Hepatology</i> , 2006, 44, S238.	3.7	0
300	646 Once-weekly compared with daily alendronate for low bone mass in women with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, S239-S240.	3.7	0
301	[674] PRESENTATION, COURSE, AND OUTCOME OF A SINGLE-CENTRE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: CHANGES THROUGH THREE DECADES. <i>Journal of Hepatology</i> , 2007, 46, S255.	3.7	0
302	Risk factors for fracture and osteopenia in primary biliary cirrhosis. <i>Bone</i> , 2009, 44, S387.	2.9	0
303	Lithocholic acid decreases cell survival and downregulates the effects of vitamin d3 on primary human osteoblasts. <i>Bone</i> , 2009, 44, S319-S320.	2.9	0
304	106 IDENTIFICATION OF AN EXTREMELY BENIGN ASYMPTOMATIC PRESENTATION IN A LARGE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS. <i>Journal of Hepatology</i> , 2009, 50, S44.	3.7	0
305	662 CHARACTERIZATION OF PEPTIDES AND PROTEINS CAPTURED BY THE MARS SYSTEM IN PATIENTS WITH CHOLESTASIS AND RESISTANT PRURITUS. <i>Journal of Hepatology</i> , 2009, 50, S243.	3.7	0
306	1306 URSODEOXYCHOLIC ACID NEUTRALIZES THE NOXIOUS EFFECTS OF LITHOCHOLIC ACID AND BILIRUBIN ON OSTEOBLASTS. <i>Journal of Hepatology</i> , 2011, 54, S515.	3.7	0

#	ARTICLE	IF	CITATIONS
307	1299 PROMISING EFFECTS OF BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND INCOMPLETE RESPONSE TO URSODEOXYCHOLIC ACID. <i>Journal of Hepatology</i> , 2011, 54, S512.	3.7	0
308	38 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS. <i>Journal of Hepatology</i> , 2012, 56, S17.	3.7	0
309	970 SERUM ALIOTAXIN ACTIVITY IS ASSOCIATED WITH PRURITUS AND DISEASE DURATION AND SEVERITY IN PRIMARY BILIARY CIRRHOSIS. <i>Journal of Hepatology</i> , 2012, 56, S379-S380.	3.7	0
310	930 DECREASE OF LIVER STIFFNESS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID. <i>Journal of Hepatology</i> , 2013, 58, S384.	3.7	0
311	950 PROGNOSIS OF PRIMARY BILIARY CIRRHOSIS WITH FEATURES OF AUTOIMMUNE HEPATITIS OVERLAP SYNDROME. ROLE OF URSODEOXYCHOLIC ACID IN LONG-TERM SURVIVAL. <i>Journal of Hepatology</i> , 2013, 58, S391.	3.7	0
312	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S388.	3.7	0
313	OC-030 – Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. <i>Gut</i> , 2014, 63, A15-A16.	12.1	0
314	P347 INCIDENCE AND RISK FACTORS FOR EXTRA-HEPATIC MALIGNANCIES (EM) IN PRIMARY BILIARY CIRRHOSIS: A COMPARATIVE STUDY FROM TWO EUROPEAN REFERRAL CENTERS. <i>Journal of Hepatology</i> , 2014, 60, S182-S183.	3.7	0
315	P463 PHB1 PROTECTIVE ROLE IN PRIMARY BILIARY CIRRHOSIS. <i>Journal of Hepatology</i> , 2014, 60, S223.	3.7	0
316	P372 APOPTOSIS INDUCED BY BILIRUBIN AND LITHOCHOLIC ACID IN HUMAN OSTEOBLASTS IS NEUTRALIZED BY URSODEOXYCHOLIC ACID. <i>Journal of Hepatology</i> , 2014, 60, S192.	3.7	0
317	Incidence and risk factors for extra-hepatic malignancies in primary biliary cirrhosis: A comparative study from two European referral centers. <i>Digestive and Liver Disease</i> , 2014, 46, e29.	0.9	0
318	P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients. <i>Journal of Hepatology</i> , 2015, 62, S795.	3.7	0
319	PWE-096 – Non-invasive assessment of disease severity in primary sclerosing cholangitis (psc): clinical scores, transient elastography (te) and the enhanced liver fibrosis (elf) test: Abstract PWE-096 Table 1. <i>Gut</i> , 2015, 64, A254.1-A254.	12.1	0
320	Preface. <i>Digestive Diseases</i> , 2015, 33, 1-1.	1.9	0
321	P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts. <i>Journal of Hepatology</i> , 2015, 62, S782-S783.	3.7	0
322	P1159 : Identification of serum metabolites associated with cholestatic pruritus. <i>Journal of Hepatology</i> , 2015, 62, S787-S788.	3.7	0
323	P1207 : Fatigue in primary biliary cirrhosis: similar prevalence to the population from the same geographic area, and association with comorbidities and severity of cholestasis. <i>Journal of Hepatology</i> , 2015, 62, S809.	3.7	0
324	The ALT/AST Ratio and Total Protein Level Identify the Autoimmune Etiology in Patients with Fulminant Hepatitis. <i>Journal of Hepatology</i> , 2016, 64, S429-S430.	3.7	0

#	ARTICLE	IF	CITATIONS
325	Ursodeoxycholic Acid Modulates the Effects of Lithocholic Acid and Bilirubin on the Gene Expression Profiling in Osteoblastic Cells. <i>Journal of Hepatology</i> , 2016, 64, S648.	3.7	0
326	An appealing new agent for treating cholestatic pruritus. <i>Lancet, The</i> , 2017, 389, 1078-1080.	13.7	0
327	Early predictive factors of corticosteroids response in patients with severe/acute or fulminant autoimmune hepatitis. <i>Journal of Hepatology</i> , 2017, 66, S549.	3.7	0
328	Juan Rod�s. A successful and extraordinary life of a visionary hepatologist. <i>Gut</i> , 2017, 66, 736-736.	12.1	0
329	Effect of obeticholic acid treatment in patients with primary biliary cholangitis on categorical shifts in GLOBE score. <i>Journal of Hepatology</i> , 2017, 66, S106.	3.7	0
330	Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years. <i>Journal of Hepatology</i> , 2017, 66, S358.	3.7	0
331	Advances in treatment options for patients with primary biliary cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 847-857.	0.8	0
332	FRI0573�...Osteocytes are involved in the pathogenesis of osteoporosis in chronic cholestasis. effects of bilirubin and bile acids on osteocytic cell lines. , 2017, , .		0
333	PWE-080�...Change in bilirubin with obeticholic acid in primary biliary cholangitis patients with high baseline bilirubin. , 2018, , .		0
334	Hepatobiliary and non-hepatobiliary malignancies in PSC patients from Southern Europe: a comparative study in two European centers. <i>Digestive and Liver Disease</i> , 2018, 50, e354.	0.9	0
335	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years. <i>Journal of Hepatology</i> , 2018, 68, S218-S219.	3.7	0
336	Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2018, 68, S219-S220.	3.7	0
337	Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis. <i>Journal of Hepatology</i> , 2018, 68, S222-S223.	3.7	0
338	Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis� the Global PBC Study Group. <i>Journal of Hepatology</i> , 2018, 68, S229-S230.	3.7	0
339	Change in bilirubin with obeticholic acid treatment in primary biliary cholangitis patients with high baseline bilirubin: a retrospective analysis of POISE, 201, and 202. <i>Journal of Hepatology</i> , 2018, 68, S232.	3.7	0
340	A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2018, 68, S230.	3.7	0
341	FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e392-e393.	3.7	0
342	FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e398.	3.7	0

#	ARTICLE	IF	CITATIONS
343	ATU-09â€¦Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
344	Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase. Digestive and Liver Disease, 2020, 52, e4-e5.	0.9	0
345	Tratamiento de las complicaciones Ã³seas. GastroenterologÃa Y HepatologÃa, 2004, 27, 45-51.	0.5	0
346	Psicosis y diferencias sociales: Comparando la prevalencia de las psicosis en dos medios urbanos diferenciados. Revista De La AsociaciÃ³n EspaÃ±ola De NeuropsiquiatrÃa, 2010, 30, .	0.1	0
347	Ursodeoxycholic acid protects osteoblastic cells from bilirubin and lithocholic acid induced apoptosis. Bone Abstracts, 0, , .	0.0	0
348	Activation of the mouse \$alpha;2(I) collagen gene promoter by acetaldehyde. Hepatology, 1993, 18, A152.	7.3	0
349	Protective effect of S-adenosyl-L-methionine (SAME) in the development of CCl4-induced cirrhosis. Hepatology, 1994, 19, 147.	7.3	0
350	Bone Disease in Patients with Cirrhosis. , 2015, , 295-305.		0
351	Gene expression profiling of osteoblastic cells cultured with lithocholic acid or bilirubin. Implications in the pathogenesis of osteoporosis in liver diseases. Bone Abstracts, 0, , .	0.0	0
352	Effect of Obeticholic Acid Treatment in Patients With Primary Biliary Cholangitis on Categorical Shifts in GLOBE Score. American Journal of Gastroenterology, 2017, 112, S495.	0.4	0
353	SAT0068â€¦Bilirubin promotes down-regulation of runx2 and up-regulation of rankl gene expression in bone explants and in osteoblastic and osteocytic cell lines. , 2018, , .		0
354	Response to Granito et al.. American Journal of Gastroenterology, 2021, 116, 217-217.	0.4	0
355	La esquizofrenia en atenciÃ³n primaria: el estudio SASPE (seÃ±ales de alerta y sÃntomas prodrÃomicos de Tj ETQq <sub>1,4</sub> 0.784314 rgBT <sub>0</sub> )		0